Pharsight

Drugs that contain Bimatoprost

1. Durysta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8629185 ALLERGAN INC 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-N-ethyl-hept-5-enamide (bimatoprost) in crystalline form II, methods for preparation, and methods for use thereof
Jul, 2031

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10398707 ALLERGAN INC Hypotensive lipid-containing biodegradable intraocular implants and related implants
Apr, 2024

(a month from now)

US8673341 ALLERGAN INC Intraocular pressure reduction with intracameral bimatoprost implants
Feb, 2025

(11 months from now)

US9149428 ALLERGAN INC Processes for making cyclic lipid implants for intraocular use
Dec, 2026

(2 years from now)

US10441543 ALLERGAN INC Processes for making cyclic lipid implants for intraocular use
Dec, 2026

(2 years from now)

US8206737 ALLERGAN INC Hypotensive lipid-containing biodegradable intraocular implants and related methods
Apr, 2027

(3 years from now)

US7799336 ALLERGAN INC Hypotensive lipid-containing biodegradable intraocular implants and related methods
Apr, 2029

(5 years from now)

US9980974 ALLERGAN INC Prostamide-containing intraocular implants and methods of use thereof
Oct, 2034

(10 years from now)

US9492316 ALLERGAN INC Prostamide-containing intraocular implants and methods of use thereof
Oct, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Mar 4, 2023

Market Authorisation Date: 04 March, 2020

Treatment: Reduction of intraocular pressure (iop) in patients with open angle glaucoma(oag) or ocular hypertension (oht) with a biodegradable bimatoprost implant

Dosage: IMPLANT;OPHTHALMIC

More Information on Dosage

DURYSTA family patents

Family Patents

2. Latisse patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8038988 ALLERGAN Method of enhancing hair growth
Aug, 2023

(6 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8263054 ALLERGAN Method of enhancing hair growth
Jan, 2023

(1 year, 1 month ago)

US9226931 ALLERGAN Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
Jan, 2023

(1 year, 1 month ago)

US8632760 ALLERGAN Method of enhancing hair growth
Jan, 2023

(1 year, 1 month ago)

US8758733 ALLERGAN Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
Jan, 2023

(1 year, 1 month ago)

US9216183 ALLERGAN Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
Jan, 2023

(1 year, 1 month ago)

US8986715 ALLERGAN Method of enhancing hair growth
Jan, 2023

(1 year, 1 month ago)

US8101161 ALLERGAN Method of enhancing hair growth
May, 2024

(2 months from now)

Market Authorisation Date: 24 December, 2008

Treatment: Method of increasing eyelash growth including length, thickness, darkness and/or number of eyelashes by administering bimatoprost to an eyelid margin; Method of increasing growth of hair including eye...

Dosage: SOLUTION/DROPS;TOPICAL

How can I launch a generic of LATISSE before it's drug patent expiration?
More Information on Dosage

LATISSE family patents

Family Patents

3. Lumigan patents expiration

LUMIGAN's oppositions filed in EPO
LUMIGAN Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7851504 ABBVIE INC Enhanced bimatoprost ophthalmic solution
Jun, 2027

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8278353 ABBVIE INC Enhanced bimatoprost ophthalmic solution
Mar, 2025

(1 year, 14 days from now)

US8586630 ABBVIE INC Enhanced bimatoprost ophthalmic solution
Mar, 2025

(1 year, 14 days from now)

US9155716 ABBVIE INC Enhanced bimatoprost ophthalmic solution
Mar, 2025

(1 year, 14 days from now)

US8338479 ABBVIE INC Enhanced bimatoprost ophthalmic solution
Mar, 2025

(1 year, 14 days from now)

US8772338 ABBVIE INC Enhanced bimatoprost ophthalmic solution
Mar, 2025

(1 year, 14 days from now)

US8299118 ABBVIE INC Enhanced bimatoprost ophthalmic solution
Mar, 2025

(1 year, 14 days from now)

US9241918 ABBVIE INC Enhanced bimatoprost ophthalmic solution
Mar, 2025

(1 year, 14 days from now)

US8933120 ABBVIE INC Enhanced bimatoprost ophthalmic solution
Mar, 2025

(1 year, 14 days from now)

US8933127 ABBVIE INC Enhanced bimatoprost ophthalmic solution
Mar, 2025

(1 year, 14 days from now)

US8524777 ABBVIE INC Enhanced bimatoprost ophthalmic solution
Mar, 2025

(1 year, 14 days from now)

US8309605 ABBVIE INC Enhanced bimatoprost ophthalmic solution
Mar, 2025

(1 year, 14 days from now)

Market Authorisation Date: 31 August, 2010

Treatment: A method of reducing intraocular pressure in patients with open angle glaucoma or ocular hypertension; A method of lowering intraocular pressure; A method of treating a patient with glaucoma or ocular...

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of LUMIGAN before it's drug patent expiration?
More Information on Dosage

LUMIGAN family patents

Family Patents